BACKGROUND:Women who initiate antiretroviral therapy (ART) during pregnancy are reported to have lower risk of preterm birth compared with those who enter pregnancy care already receiving ART. We hypothesize this association can be largely attributed to selection bias. METHODS: We simulated a cohort of 1000 preconceptional, HIV-infected women, where half were randomly allocated to receive immediate ART and half to delay ART until their presentation for pregnancy care. Gestational age at delivery was drawn from population data unrelated to randomization group (i.e., the true effect of delayed ART was null). Outcomes of interest were preterm birth (<37 weeks), very preterm birth (<32 weeks), and extreme preterm birth (<28 weeks). We analyzed outcomes in 2 ways: (1) a prospectively enrolled clinical trial, where all women were considered (the intent-to-treat (ITT) analysis); and (2) an observational study, where women who deliver before initiating ART were excluded (the naïve analysis). We explored the impact of later ART initiation and gestational age measurement error on our findings. RESULTS: Preconception ART initiation was not associated with preterm birth in ITT analyses. Risk ratios (RRs) for the effect of preconception ART initiation were RR = 1.10 (preterm), RR = 1.41 (very preterm), and RR = 5.01 (extreme preterm) in naïve analyses. Selection bias increased in the naïve analysis with advancing gestational age at ART initiation and with introduction of gestational age measurement error. CONCLUSIONS: Analyses of preterm birth that compare a preconception exposure to one that occurs in pregnancy are at risk of selection bias. See video abstract at, http://links.lww.com/EDE/B313.
RCT Entities:
BACKGROUND:Women who initiate antiretroviral therapy (ART) during pregnancy are reported to have lower risk of preterm birth compared with those who enter pregnancy care already receiving ART. We hypothesize this association can be largely attributed to selection bias. METHODS: We simulated a cohort of 1000 preconceptional, HIV-infectedwomen, where half were randomly allocated to receive immediate ART and half to delay ART until their presentation for pregnancy care. Gestational age at delivery was drawn from population data unrelated to randomization group (i.e., the true effect of delayed ART was null). Outcomes of interest were preterm birth (<37 weeks), very preterm birth (<32 weeks), and extreme preterm birth (<28 weeks). We analyzed outcomes in 2 ways: (1) a prospectively enrolled clinical trial, where all women were considered (the intent-to-treat (ITT) analysis); and (2) an observational study, where women who deliver before initiating ART were excluded (the naïve analysis). We explored the impact of later ART initiation and gestational age measurement error on our findings. RESULTS: Preconception ART initiation was not associated with preterm birth in ITT analyses. Risk ratios (RRs) for the effect of preconception ART initiation were RR = 1.10 (preterm), RR = 1.41 (very preterm), and RR = 5.01 (extreme preterm) in naïve analyses. Selection bias increased in the naïve analysis with advancing gestational age at ART initiation and with introduction of gestational age measurement error. CONCLUSIONS: Analyses of preterm birth that compare a preconception exposure to one that occurs in pregnancy are at risk of selection bias. See video abstract at, http://links.lww.com/EDE/B313.
Authors: Anthony M Vintzileos; Cande V Ananth; John C Smulian; William E Scorza; Robert A Knuppel Journal: Am J Obstet Gynecol Date: 2002-11 Impact factor: 8.661
Authors: Lauren E Cain; James M Robins; Emilie Lanoy; Roger Logan; Dominique Costagliola; Miguel A Hernán Journal: Int J Biostat Date: 2010 Impact factor: 0.968
Authors: Jennifer Y Chen; Heather J Ribaudo; Sajini Souda; Natasha Parekh; Anthony Ogwu; Shahin Lockman; Kathleen Powis; Scott Dryden-Peterson; Tracy Creek; William Jimbo; Tebogo Madidimalo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226
Authors: E S Machado; C B Hofer; T T Costa; S A Nogueira; R H Oliveira; T F Abreu; L A Evangelista; I F A Farias; R T C Mercadante; M F L Garcia; R C Neves; V M Costa; J S Lambert Journal: Sex Transm Infect Date: 2008-11-05 Impact factor: 3.519
Authors: Joan T Price; Jennifer Winston; Bellington Vwalika; Stephen R Cole; Marie C D Stoner; Mwansa K Lubeya; Andrew Kumwenda; Jeffrey S A Stringer Journal: Int J Gynaecol Obstet Date: 2018-10-19 Impact factor: 3.561
Authors: Joan T Price; Bellington Vwalika; Jennifer Winston; Andrew Kumwenda; Mwansa K Lubeya; Katelyn J Rittenhouse; Elizabeth Stringer; Margaret P Kasaro; Jeffrey S A Stringer Journal: Int J Gynaecol Obstet Date: 2019-04-29 Impact factor: 3.561
Authors: Joan T Price; Bellington Vwalika; Jessie K Edwards; Stephen R Cole; Margaret P Kasaro; Katelyn J Rittenhouse; Andrew Kumwenda; Mwansa K Lubeya; Jeffrey S A Stringer Journal: J Acquir Immune Defic Syndr Date: 2021-06-01 Impact factor: 3.771
Authors: Ushma C Mehta; Cari van Schalkwyk; Prineetha Naidoo; Arthi Ramkissoon; Otty Mhlongo; Niren R Maharaj; Niree Naidoo; Karen Fieggen; Michael F Urban; Shaun Krog; Alex Welte; Mukesh Dheda; Yogan Pillay; Neil F Moran Journal: South Afr J HIV Med Date: 2019-09-30 Impact factor: 2.744
Authors: Nadia M Ikumi; Thokozile R Malaba; Komala Pillay; Marta C Cohen; Hlengiwe P Madlala; Mushi Matjila; Dilly Anumba; Landon Myer; Marie-Louise Newell; Clive M Gray Journal: AIDS Date: 2021-04-01 Impact factor: 4.177
Authors: Katelyn J Rittenhouse; Humphrey Mwape; Julie A E Nelson; John Mwale; Gabriel Chipili; Joan T Price; Michael Hudgens; Elizabeth M Stringer; Kristina De Paris; Bellington Vwalika; Jeffrey S A Stringer Journal: AIDS Date: 2021-03-15 Impact factor: 4.632